سعر انفلاكام 10 مجم 20 قرص 2024

Inflacam 10 mg dispersible tablet (piroxicam, Mepaco): non-steroidal anti-inflammatory drug of the oxicam class; 20 dispersible tablets (2 strips).

• Most common adverse reactions (>2% in clinical trials): nausea, constipation, flatulence, abdominal pain, diarrhoea, headache, dizziness, oedema and rash.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Gastrointestinal effects are the most commonly encountered; other reported effects include anaemia, oedema (mainly ankle), dizziness, tinnitus, rash, pruritus, raised transaminases, renal disorders and severe cutaneous reactions.General active-ingredient information · electronic medicines compendium (emc), UK

• History of GI ulceration, bleeding or perforation; GI disorders predisposing to bleeding (ulcerative colitis, Crohn's disease, GI cancer, diverticulitis); active peptic ulcer or GI bleeding; concomitant other NSAIDs (including COX-2 inhibitors and analgesic-dose aspirin) or anticoagulants; previous serious allergic drug reaction (especially SJS/TEN/erythema multiforme) or any skin reaction to piroxicam/NSAIDs; NSAID-induced asthma, nasal polyps, angioedema or urticaria; severe heart failure; last trimester of pregnancy.General active-ingredient information · electronic medicines compendium (emc), UK
• Known hypersensitivity to piroxicam; history of asthma, urticaria or allergic-type reactions after aspirin or other NSAIDs; setting of coronary artery bypass graft (CABG) surgery.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed warning: NSAIDs increase the risk of serious cardiovascular thrombotic events (myocardial infarction, stroke), which may occur early and increase with duration, and of serious GI bleeding, ulceration and perforation that can be fatal and occur without warning; elderly patients and those with prior ulcer disease/GI bleeding are at greater risk.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Doses above 20 mg/day increase GI risk; discontinue at the first appearance of skin reactions or relevant GI events; life-threatening skin reactions (SJS/TEN) and fixed drug eruption have been reported; also monitor for hepatotoxicity, hypertension, fluid retention/heart failure and renal toxicity.General active-ingredient information · electronic medicines compendium (emc), UK, DailyMed (U.S. National Library of Medicine)

• Anticoagulants (e.g. warfarin), antiplatelets, SSRIs/SNRIsSynergistic effect on bleeding; increased risk of serious bleeding — monitor for bleeding (UK SmPC contraindicates use with anticoagulants).DailyMed (U.S. National Library of Medicine)
• LithiumNSAIDs raise plasma lithium and reduce renal lithium clearance; monitor for lithium toxicity.DailyMed (U.S. National Library of Medicine)
• MethotrexateMay increase the risk of methotrexate toxicity (neutropenia, thrombocytopenia, renal dysfunction); monitor.DailyMed (U.S. National Library of Medicine)
• CyclosporineMay increase cyclosporine nephrotoxicity; monitor renal function.DailyMed (U.S. National Library of Medicine)
• ACE inhibitors, ARBs, beta-blockers, diureticsNSAIDs may diminish the antihypertensive effect and, in at-risk patients, worsen renal function; monitor blood pressure and renal function.DailyMed (U.S. National Library of Medicine)

• During the first and second trimester piroxicam should not be given unless clearly necessary (lowest dose, shortest duration); from week 20 it may cause oligohydramnios from foetal renal dysfunction and ductus arteriosus constriction — consider antenatal monitoring.General active-ingredient information · electronic medicines compendium (emc), UK
• Limit dose and duration between about 20 and 30 weeks of gestation and avoid use at about 30 weeks and later (risk of premature closure of the fetal ductus arteriosus and oligohydramnios/neonatal renal impairment).General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Piroxicam appears in breast milk at about 1-3% of maternal plasma concentrations; not recommended in nursing mothers as clinical safety has not been established.General active-ingredient information · electronic medicines compendium (emc), UK

English text not available for this section.